A Study Of The Selective PKC-β Inhibitor MS- 553

Clinical trial NCT03492125 · TERMINATED

Trial details

NCT number: NCT03492125
Sponsor: MingSight Pharmaceuticals, Inc
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Aggressive Lymphoma

Start date: 2018-05-25
Primary completion: 2023-11-28
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.